来 From the Ministry of Agriculture website show that December 15, the Ministry of Agriculture received the report of the veterinary sector in Jiangsu Province, in the implementation of routine monitoring of poultry at Hai'an, Dongtai individual farmers laying hens kept in the monitoring of the H5N1 bird Etiology of influenza-positive samples. At present, these areas found no outbreak of bird flu.
Upon receiving the report, the immediate deployment of Jiangsu Province, the Ministry of Agriculture veterinary departments to implement the prevention and control measures.
First, the monitoring of positive flocks and the surrounding areas to carry out culling of poultry have been culled 377,000 poultry. 二是实行隔离监控。 The second is to monitor the implementation of isolation. Prohibit the transfer of Dongtai and Hai'an all poultry and their products, limiting the flow. 三是消毒灭源。 The third is to eliminate the source of disinfection. The culling of poultry on farms (households) and its surrounding areas to carry out thorough disinfection of the environment to prevent virus spread.
In the previous 9, the Hong Kong SAR Government Secretary for Food and Health York Chow said at a chicken farm in Yuen Long, New Territories samples of dead chickens and chicken samples confirmed H5 avian flu virus were positive, but there is no report of bird flu. On the chicken farm has been identified as a spot, chicken farms within three kilometers range has been identified as infected, infected two chicken farms were 80,000 chickens will be destroyed. The departments concerned to start the original Alert Response Level, Serious Response Level promoted. Will stop the supply of live chickens in Hong Kong for 21 days.
There are brokerage Fellow assessment, Jiangsu, Hong Kong, the "warning" for large-scale development of the epidemic is unlikely, the impact of the related companies are mainly short-term price stimulus. The outbreak of the current size, the company's actual results to have an impact, but it will not reach a significant level. Shares in animal husbandry from the news that the Hong Kong avian flu "warning" has not yet been invited to the bird flu vaccine caused by the actual effect.
Related to listed companies
Shares in animal husbandry: Company is the first approved by the State Ministry of Agriculture, the bird flu vaccine production enterprise, production capacity of more than 13 billion Haneda (copies), the product of about 60 percent gross margin, which is highly profitable products. At present, formal approval by the Ministry of Agriculture 9 sentinel poultry influenza vaccine production enterprises, Nanjing Merial (50%) and biological Qianyuan-ho (accounting for 52.92 percent) are company-owned subsidiary.Nanjing Merial is the world's largest manufacturer of animal vaccines, biological products Qianyuan-ho also exported to Southeast Asia, the epidemic-hit areas. Main products include poultry vaccines, veterinary vaccines, the special three-part vaccine is the most wide variety of domestic products, the largest production capacity, quality, excellent stability, the market share of the first backbone enterprises. Animal vaccines has been in production more than 20 billion copies plume, accounting for more than one-third market share. Companies to invest 38 million yuan in Jiangxi building in line with the GMP requirements for swine, pet vaccine production base; invest 42.5 million yuan in Lanzhou biological pharmaceutical GMP standards in line with the new production workshop, the new workshop has a two production lines for the production of special vaccines and synthetic peptide vaccines, packaging design and production capacity of two billion milliliters per year.
Kim Group: Company's Inner Mongolia Autonomous Region biopharmaceuticals plant is the only company to produce animal vaccines manufactured enterprises, the Ministry of Agriculture is also designated special vaccine livestock production enterprises, bird flu vaccine research and production capacity of UN-leading domestic level. Take the lead in the country received bivalent vaccine production symbol will be "O type - Asia 1 type foot and mouth disease vMDV Bivalent inactivated vaccine" as a high-end products, the first to enter the market, the company leading product's market share further improved.
Westlands Biological: human bird flu vaccine: the company with the Chinese Academy of Military Medical Sciences shared with avian influenza vaccine has completed pre-clinical research, test and review after the passage, the company pandemic influenza vaccine will enter clinical cracking stage.
Tiantan Biological (600,161) (600,161): the company controlling shareholder Beijing Institute of Biological Products and the Chinese Academy of Military Medical Sciences will jointly assume the second person with the Mainland of China bird flu vaccine research and development projects, and the last vaccine production may be completed by the company is expected to become the research results are translated into.
Zhejiang Medicine: Company anti-bird flu drug breakthrough technology, the highly effective drugs that can inhibit the bird flu virus strain neuraminidase, can also be used for the treatment of a pandemic from avian flu virus strain redistribution and the formation of A-type influenza caused by the influenza virus strains, belonging to an internationally recognized anti-bird flu drug.
Sublimation Utterback: formal approval by the state Department of Agriculture 9 sentinel poultry influenza vaccine production enterprises, Qingdao prone state bio-engineering companies (38%) for the company subsidiaries.
Lianhuan Pharmaceutical: companies have a bird flu vaccine (H9 subtypes, F strain), Newcastle disease live vaccine edge low toxicity (La Sota strain) vaccine products, such as access to the Ministry of Agriculture six production approval of veterinary drugs and put into production, which with Yangzhou University in Yangzhou, such as the formation of bio-engineering Wick Limited (registered capital of 58.4 million yuan, the company accounted for 39.38%) mainly produce bird flu vaccine is expected to be an annual output of poultry vaccines plume of 1.6 billion, annual sales revenue reached 120 million yuan, net profit of up to 27.729 million yuan, 60 percent gross margin, with higher profitability.
Shanghai Pharmaceutical: in Switzerland, Roche announced the opening of its anti-influenza drug treatment of avian flu drug "Tamiflu" right after the production, the company controlling shareholder of the drug group in mid-December 2005 became the first to be authorized by the production of medicine production enterprises, will be entitled to production "of" Chinese Edition "of" Tamiflu "generic drugs, but the" Tamiflu "sales channels limited to government procurement, at present, the whole group on the drug Tamiflu link of all sales by the company agent to do.
|
No comments:
Post a Comment